FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to the field of medicine and pharmacy and concerns a pharmaceutical composition for the prevention and/or treatment of HIV infection containing an active pharmaceutical substance (APS) selected from darunavir ethanolate (DRV-E), darunavir amorphous (DRV-A), efavirenz (EFV), ritonavir polymorphic form 1 (RTV-P1) and ritonavir polymorphic form 2 (RTV-P2) containing a mesoporous sorbent (MS), selected from mesoporous silicon dioxide and mesoporous magnesium aluminometasilicate, a pharmaceutically acceptable polymer and excipients with a mass ratio of AFS:MS from 1:1 to 1:3.
EFFECT: increase in the solubility of APS, which increases its bioavailability and reduces the drug load on the patient’s body.
5 cl
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID PHARMACEUTICAL COMPOSITION FOR MANUFACTURING ORAL ANTIRETROVIRAL THERAPEUTIC AGENT | 2020 |
|
RU2760129C1 |
| METHOD FOR APPLICATION OF COPOLYMER OF DIMETHYLAMINOETHYLMETHACRYLATE, BUTYLMETHACRYLATE AND METHYL METHACRYLATE TO INCREASE SOLUBILITY AND/OR BIOAVAILABILITY OF ANTIRETROVIRAL ACTIVE PHARMACEUTICAL SUBSTANCE IN MANUFACTURE OF SOLID DISPERSION ON GRANULAR CARRIER | 2020 |
|
RU2759547C1 |
| PHARMACEUTICAL COMPOSITION HAVING ANTI-HIV INFECTION ACTIVITY | 2017 |
|
RU2659693C1 |
| SOLID ORAL DOSAGE FORM PROLONGED RELEASING ACTIVE PHARMACEUTICAL SUBSTATION (APS) IN UPPER PART OF STOMACH | 2021 |
|
RU2786063C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING HIV INFECTION, METHOD FOR PREPARING IT, AND METHOD OF TREATING | 2012 |
|
RU2505286C1 |
| PHARMACEUTICAL COMPOSITION FOR HIV INFECTION TREATMENT | 2016 |
|
RU2619840C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING HIV-INFECTION, METHOD FOR PREPARING AND METHOD OF USING | 2013 |
|
RU2543322C1 |
| CENICRIVIROC COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2014 |
|
RU2633069C2 |
| ANTI-RETROVIRAL COMBINATION | 2014 |
|
RU2675831C2 |
| COMPOSITIONS AND METHODS FOR THERAPEUTIC MEANS DELIVERY | 2011 |
|
RU2632445C2 |
